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Summary Some studies have suggested that the S allele of the MYCL oncogene, which results from an
intragenic EcoRI restriction fragment length polymorphism (RFLP), may be associated with cancer
susceptibility. In addition, this allele has also been linked to metastases and adverse survival in certain
cancers, although studies of lung cancer patients from different populations have yielded controversial results.
We studied 108 cases of surgical resected non-small-cell lung cancer (NSCLC) and found no evidence that
MYCL gentotypes were associated with tumour progression or a worse prognosis. However, the presence of
loss of heterozygosity (LOH) at this chromosome lp32 locus correlated significantly with regional lymph node
involvement, as well as advanced TNM stage. These data indicate the existence of a chromosome lp candidate
tumour-suppressor gene(s), possibly in linkage disequilibrium with the EcoRI RFLP in specific populations,
which appears to play a role in determining tumour progression in NSCLC. Refined mapping of the critical
region of loss should help attempts to identify and clone the candidate gene.
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In many western countries, including Australia, lung cancer is
the commonest malignancy in males and the largest cause of
cancer deaths. While conventional management has not
dramatically changed lung cancer mortality rates, molecular
developments have expanded our understanding of the
mechanisms leading to lung tumorigenesis, leading to efforts
to use these discoveries to optimise the treatment of lung
cancer.
A potential molecular marker associated with cancer
susceptibility, as well as metastases and adverse survival, is
the MYCL oncogene. This gene contains an EcoRI restriction
fragment length polymorphism (RFLP), which allows
genotyping into either L or S alleles.
In terms ofcancer susceptibility, the S allele of MYCL was
more common in patients with non-Hodgkin's lymphoma
(Crossen et al., 1994), and male patients with bone and soft-
tissue sarcomas (Kato et al., 1990). In addition, the SS
genotype was more frequent in colorectal cancer patients
than in young blood donor controls (Young et al., 1994).
However, the cancer-susceptibility model is controversial, as
the SS genotype appears to protect against hepatocellular
cancer (Taylor et al., 1993), and the S allele was not increased
in patients with lung cancer (Tamai et al., 1990; Weston et
al., 1992, 1994), breast cancer (Champeme et al., 1992) or
lymphoma/leukaemia (Chenevix-Trench et al., 1989).
As regards tumour progression, Kawashima et al. (1988,
1992), in an initial study followed by a larger study involving
252 Japanese lung cancer patients, showed that the S allele
predisposed to metastases and adverse prognosis. Conversely,
this association has not been found in Caucasian (Norwegian
and North American) lung cancer populations (Tamai et al.,
1990; Tefre et al., 1990; Weston et al., 1992, 1994). While the
conflicting results may have been owing to racial/ethnic
differences, there were also significant methodological
variations between the studies, such as case stratification,
including heterogeneity in the subtypes of lung cancer,
disease stage and treatment modalities; all factors which are
known to affect tumour progression and outcome.
To address some of these possible confounders, we
investigated the relationship of MYCL genotypes to tumour
stage, nodal metastases and survival in a well-defined,
homogeneous lung cancer subset; histologically diagnosed
NSCLC patients who had curative surgery as their primary
treatment and who had. comprehensive post-surgical staging
and follow-up.
Materials and methods
DNA was obtained from 108 cases of post-surgically staged,
resected NSCLC and normal lung tissue from patients at The
Prince Charles Hospital, Brisbane, Australia as previously
described (Fong et al., 1995).
The MYCL gene was discovered as two additional DNA
fragments of 10.0 kb and 6.6 kb when the MYC gene was
used to probe EcoRI digested human genomic DNA (Nau et
al., 1985). These fragments represent a RFLP at the MYCL
locus, situated in the second intron (Kaye et al., 1988). This
RFLP can also be revealed with polymerase chain reaction
(PCR) using primers, which flank a 267 bp DNA fragment
containing this polymorphism, followed by EcoRI digestion
to yield the uncut L allele or the cut S allele of 142 and
125 bp (Tamai et al., 1990). DNA from tumour tissue and
corresponding normal lung of each patient was examined for
this RFLP. Standard PCR conditions were used with
restriction enzyme digestion performed according to manu-
facturer's instructions. PCR products were electrophoretically
fractionated in 12% polyacrylamide gels with 10% glycerol
and visualised after ethidium bromide staining.
Tumour DNA was also examined for LOH using PCR to
amplify a highly polymorphic Alu variable polyA micro-
satellite marker 16 kb upstream of the MYCL locus (Makela
et al., 1992), as previously described (Fong et al., 1995).
Statistical analysis included X2, t-test and ANOVA
(Dawson-Saunders and Trapp, 1990), as well as log-rank
analysis of Kaplan-Meier survival curves with a median
follow-up duration of 23 months.
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Results
The MYCL genotype resulting from an EcoRI RFLP was
determined in 108 cases of NSCLC and was identical in the
tumour and normal tissue of each patient. There were 30
cases (28%) homozygous for the L allele, 53 (49%)
heterozygous for the LS alleles and 25 (23%) homozygousMYCL genotypes and LOH in lung cancer
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for the S allele (Figure 1). The L and S allele frequencies were
0.523 and 0.477 respectively, similar to the frequencies
reported by Nau et al. (1985), and the genotypes were
found to be in accord with Hardy-Weinberg equilibrium
(P=0.987, x2).
There was no difference between the genotypes of the two
major NSCLC subtypes; squamous cell carcinoma (SCC) and
adenocarcinoma. There was also no correlation of the
genotypes with either age, sex, smoking history, T, N or
TNM stage (Table I).
Furthermore, neither the S allele (LS and SS genotypes)
nor homozygosity for the S allele (SS genotype) was
associated with T, N or TNM stage (Table II). In addition,
there was no difference in the survival of patients with the SS,
LS or LL genotypes [P=0.881, log-rank (data not shown)].
(a)
DNA marker NL LC
(b)
NL LC
(c)
NL LC
Neither was there a survival difference when the S allele (LS
and SS genotypes) was compared with the LL genotype
[P=0.856, log-rank (data not shown)].
Using a highly polymorphic microsatellite marker just
upstream of MYCL (Makela et al., 1992), we found that 85
of our cases were informative for loss of heterozygosity
(LOH) analysis, whereas three cases had microsatellite
instability and were excluded from LOH analysis (Fong et
al., 1995). Twenty-three of these 85 (27%) informative cases
showed LOH at the MYCL locus (Figure 2).
Table II Tumour stage and various MYCL genotypes
P-value P-value
LL LS/SS (x2) LL/LS SS (x2)
T stage
1 7 23 24 6
2, 3, 4 23 55 0.522 59 19 0.630
N stage
0 20 49 49 20
1, 2 10 29 0.709 34 5 0.057
TNM stage
I 18 43 43 18
II, III 12 35 0.647 40 7 0.074
Figure 1 Representative examples of the possible MYCL EcoRI
RFLP genotypes in paired normal and tumour tissue in
individuals with NSCLC. (a) LL homozygote; (b) SS homo-
zygote; (c) LS heterozygote. NL, normal lung; LC, lung cancer.
The marker band sizes (bp) are from top to bottom: 587, 458,
437, 323, 289, 267, 241, 171 and 142.
Figure 2 Representative examples of LOH at the MYCL locus in
paired normal and tumour tissue. In each case, normal lung DNA
(NL) is in the left lane and lung cancer DNA (LC) is in the right
lane, and arrows indicate the deleted alleles.
Table I The clinicopathological features of NSCLC patients (n= 108) according to MYCL genotype and allelic status (LOH)
MYCL genotype Allelic status
LL LS SS P-value (x2) Informative, no LOH LOH P-value (X2)
Total number (%) 30 (28) 53 (49) 25 (23) 62 (73) 23 (27)
Subtype
SCC 10 22 11 21 13
Adenocarcinoma 16 20 10 0.490 33 5 0.014
Large cell carcinoma 1 2 1 1 1
Carcinoid/atypical carcinoid 1 2 1 2 1
Adenosquamous 2 7 2 5 3
Mean age (years) 61.9 61.9 58 0.288 61 62.7 0.492
(ANOVA) (t-test)
Sex
Male 22 38 16 43 20
Female 8 15 9 0.720 19 3 0.099
Smoking history
Never 3 4 2 5 1
Past or current 27 49 23 0.926 57 22 0.552
Pack-years smoked 37.2 44.7 42.3 0.576 40.7 49.1 0.262
(ANOVA) (t-test)
T stage
1 7 17 6 20 5
2,3,4 23 36 19 0.618 42 18 0.344
N stage
0 20 29 20 46 8
1,2 10 24 5 0.089 16 15 0.001
TNM stage
I 18 25 18 40 7
II, III 12 28 7 0.107 22 16 0.005MYCL genotypes and LOH in lung cancer
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Discussion
Our data do not support a role for the S allele of the MYCL
gene in determining tumour progression or survival in
patients with resected NSCLC in Australia. These data,
together with other negative studies in Caucasian and
African-American populations (Tamai et al., 1990; Tefre et
al., 1990; Weston et al., 1992, 1994), are in direct contrast to
the Japanese studies (Kawashima et al., 1988, 1992).
While it is possible that the adverse clinicopathological
association of the S allele only applies to Japanese lung
cancer patients, studies of other cancers within this
population have shown conflicting results, thereby indicating
possible tissue specificity. For instance, the S allele was
associated with metastases in renal (Kakehi and Yoshida,
1989) and gastric cancers (Ishizaki et al., 1990), but not
colorectal or breast cancers (Ikeda et al., 1988; Ishizaki et al.,
1990) in Japanese patients. Several studies of cancers other
than lung in non-Japanese populations have also linked the S
allele with tumour progression. The S allele was associated
with tumour size and a lack of differentiation in Indian oral
cancer patients (Saranath et al., 1990), and lung metastases in
Caucasian breast cancer patients (Champeme et al., 1992).
Furthermore, the SS genotype was associated with a
worsening clinicopathological stage in Australian colorectal
patients recruited from the same region in Queensland as our
cases (Young et al., 1994).
On the other hand, independent studies have now
consistently shown a lack of an adverse impact for the S
allele in a variety of Caucasian lung cancer patients,
questioning the validity of these observations. While an
alternative explanation is that these studies were too
insensitive to detect an association, another possibility is
that the RFLP within certain populations (ethnic groups)
may be in linkage disequilibrium with a gene that is critical to
tumour progression and survival. In this regard, it has been
demonstrated that the frequency of the EcoRI RFLP varies
by race (Weston et al., 1994). We thus investigated whether
LOH, a hallmark feature of tumour-suppressor genes, was
present in this chromosomal region.
Although LOH at the lp32 MYCL locus was not found in
Kawashima's initial study (Kawashima et al., 1988), LOH at
lp has since been described in approximately 15-18% of
NSCLCs (Sato et al., 1994; Tsuchiya et al., 1992).
Furthermore, new highly polymorphic microsatellite markers
have also improved LOH analysis. Using such a marker just
upstream of MYCL (Makela et al., 1992), we found that 23
of the 85 (27%) informative cases showed LOH. It should be
noted that while the presence of gene amplification may cause
false-positive LOH results by microsatellite analysis (Nagai et
al., 1994), this is an unlikely confounder here because MYCL
is rarely (<1%) amplified in NSCLC (Bergh, 1990; Shiraishi
et al., 1989; Slebos et al., 1989; Yokota et al., 1988).
As for clinicopathological features (Table I), the frequency
of LOH was significantly higher in SCCs (13/34, 38%)
compared with the adenocarcinomas (5/38, 13%; P=0.014,
x2). Whereas LOH was not associated with age, sex or
smoking, it correlated significantly with: (1) hilar and/or
mediastinal lymph node involvement (P=0.001, X2); and (2)
advanced TNM stages (P=0.005, x2), indicating that LOH at
lp32 may be a factor in determining tumour progression in
NSCLC. There was, however, no survival difference between
the NSCLC cases with and without MYCL LOH [P=0.101,
log-rank (data not shown)], which may have been owing to
the relatively limited follow-up duration of these surgically
treated patients who are known to have the best prognosis of
lung cancer sufferers.
This study thus suggests that there may be a tumour-
suppressor gene(s) in NSCLC on chromosome lp, particu-
larly in SCCs, which affects tumour progression. There are
similar findings in other cancers; LOH at MYCL correlated
with shorter survival after relapse (Bieche et al., 1990), while
LOH at lp correlated with nodal metastases (Borg et al.,
1992) in breast cancer. LOH at lp has also been described in
other tumours, including neuroblastoma (Weith et al., 1989),
melanoma (Dracopoli et al., 1989), Wilms' tumours (Grundy
et al., 1994), phaeochromocytoma (Tsutsumi et al., 1989) and
colon cancer (Laurent-Puig et al., 1992). More evidence
comes from the recent report that allelic loss of 1p was a
strong prognostic factor in patients with neuroblastoma,
independent of age and stage (Caron et al., 1996). In
addition, somatic cell hybrid experiments have shown that
the loss of chromosome 1 was associated with the malignant
phenotype (Stoler and Bouck, 1985).
As we only investigated LOH at MYCL and did not
specifically map the critical region of genetic loss, it is
possible that MYCL is not the target gene but may just be
deleted coincidentally. For instance, the critical region of loss
appears to be distal to MYCL in colorectal cancers (Leister et
al., 1990), whereas multiple areas of LOH have been
identified in breast cancer, including one just proximal to
MYCL (Hoggard et al., 1995). Consequently, candidate genes
include p18 at lp32 (Guan et al., 1994), as well as other lp
genes such as DAN (Enomoto et al., 1994), RAPlGAI (Weiss
et al., 1994) and PITSLRE (Lahti et al., 1994). The
increasing availability of closely spaced microsatellite
markers should, however, facilitate the localisation and
identification of the candidate NSCLC tumour-suppressor
gene in the minimally deleted chromosomal region (Gyapay
et al., 1994).
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